3-hydroxybutyric acid has been researched along with Abdominal Migraine in 3 studies
3-Hydroxybutyric Acid: BUTYRIC ACID substituted in the beta or 3 position. It is one of the ketone bodies produced in the liver.
3-hydroxybutyric acid : A straight-chain 3-hydroxy monocarboxylic acid comprising a butyric acid core with a single hydroxy substituent in the 3- position; a ketone body whose levels are raised during ketosis, used as an energy source by the brain during fasting in humans. Also used to synthesise biodegradable plastics.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Emerging evidence suggest migraine is a response to cerebral energy deficiency or oxidative stress in the brain." | 3.30 | Defining metabolic migraine with a distinct subgroup of patients with suboptimal inflammatory and metabolic markers. ( Fischer, D; Gross, EC; Orsini, AL; Putananickal, N; Schoenen, J; Soto-Mota, A, 2023) |
| "The primary endpoint was the number of migraine days in the last four weeks of treatment, adjusted for baseline." | 3.11 | Efficacy and safety of exogenous beta-hydroxybutyrate for preventive treatment in episodic migraine: A single-centred, randomised, placebo-controlled, double-blind crossover trial. ( Cichon, S; Fischer, D; Gocheva, V; Gross, EC; Hafner, P; Henzi, BC; Nagy, S; Orsini, AL; Putananickal, N; Rubino, D; Sandor, P; Schmidt, S; Vogt, DR, 2022) |
| "Currently available prophylactic migraine treatment options are limited and are associated with many, often intolerable, side-effects." | 2.90 | Efficacy and safety of exogenous ketone bodies for preventive treatment of migraine: A study protocol for a single-centred, randomised, placebo-controlled, double-blind crossover trial. ( Cichon, S; Fischer, D; Gross, E; Orsini, AL; Putananickal, N; Sandor, P; Schmidt, S; Vogt, DR, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Putananickal, N | 3 |
| Gross, EC | 2 |
| Orsini, AL | 3 |
| Schmidt, S | 2 |
| Hafner, P | 1 |
| Gocheva, V | 1 |
| Nagy, S | 1 |
| Henzi, BC | 1 |
| Rubino, D | 1 |
| Vogt, DR | 2 |
| Cichon, S | 2 |
| Sandor, P | 2 |
| Fischer, D | 3 |
| Schoenen, J | 1 |
| Soto-Mota, A | 1 |
| Gross, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety, Tolerability and Efficacy of Exogenous Ketone Bodies for Preventive Treatment of Migraine: A Randomised, Placebo-controlled, Double-blind Study[NCT03132233] | 42 participants (Actual) | Interventional | 2017-05-08 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for 3-hydroxybutyric acid and Abdominal Migraine
| Article | Year |
|---|---|
Efficacy and safety of exogenous beta-hydroxybutyrate for preventive treatment in episodic migraine: A single-centred, randomised, placebo-controlled, double-blind crossover trial.
Topics: 3-Hydroxybutyric Acid; Cross-Over Studies; Double-Blind Method; Humans; Migraine Disorders; Treatmen | 2022 |
Defining metabolic migraine with a distinct subgroup of patients with suboptimal inflammatory and metabolic markers.
Topics: 3-Hydroxybutyric Acid; Brain; Humans; Migraine Disorders; Oxidative Stress; Patients | 2023 |
Efficacy and safety of exogenous ketone bodies for preventive treatment of migraine: A study protocol for a single-centred, randomised, placebo-controlled, double-blind crossover trial.
Topics: 3-Hydroxybutyric Acid; Adolescent; Adult; Aged; Analgesics; Biomarkers; Brain; Cross-Over Studies; D | 2019 |